Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Date:8/31/2013

y efficacy outcome was the recurrence of symptomatic VTE, defined as the composite of recurrent symptomatic DVT, non-fatal symptomatic PE and fatal PE in patients during the 12-month study period. The principal safety outcome was clinically relevant bleeding (major or non-major) occurring during or within three days of interrupting or stopping study treatment. Secondary efficacy outcomes included the composite clinical outcome of symptomatic recurrent DVT, non-fatal symptomatic recurrent PE and all-cause mortality.1

The study is named after the famous Japanese artist and painter Katsushika Hokusai.

About Venous Thromboembolism

VTE is an umbrella term for two conditions, DVT and PE. DVT is a blood clot found anywhere in the deep veins of the legs, while PE occurs when part of a clot detaches and lodges in the pulmonary arteries, causing a potentially fatal condition.2

VTE is a major cause of morbidity and mortality worldwide with an annual incidence of approximately one per 1,000 in developed countries, including an estimated 430,000 PE events, 680,000 DVT events and 540,000 deaths each year in the EU.3,4 In the U.S., it is currently estimated that more than 950,000 VTE events and approximately 300,000 VTE related deaths occur each year.5,6 Thirty percent of people with VTE die within one month of diagnosis and about 20% of those with PE experience sudden death.7

About Edoxaban

Edoxaban is an investigational, oral, once-daily anticoagulant that specifically and reversibly inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting.8 The global edoxaban clinical trial program includes two phase 3 clinical studies, Hokusai-VTE and ENGAGE AF-TIMI 48 (Effective aNticoaGulation with Factor XA Next GEneration in Atrial Fibrillation), which are evaluating edoxaban, administered once-daily, for treatment and prevention of re
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
2. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
6. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
7. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
10. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
11. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... on December 24, 2014 it closed its previously ... raised approximately $2.3 million in gross proceeds from ... proceeds from the offering to fund its research ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... DALLAS , December 24, 2014 /PRNewswire/ ... Research Report on Global Disposable Syringe Industry ... to its online business intelligence library. ... Global Disposable Syringe Industry is a professional ... Syringe market.  For overview analysis, the report ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... its commitment to the hemophilia community, Bayer HealthCare is ... adding a community element to the internship experience.  The ... will spend five weeks of the eight-week program at ... is currently seeking applicants who are attending college and ...
... Canon Europe, world-leader in imaging solutions, has strengthened ... Netherlands-based Medical solutions specialist Delft Diagnostic Imaging (Delft DI). ...  The first area is innovative medical software solutions for ... become a future platform for the development of new ...
Cached Medicine Technology:Bayer Expands Its Hemophilia Leadership Development Program 2Bayer Expands Its Hemophilia Leadership Development Program 3Canon Europe Acquires Dutch Medical Solutions Specialist Delft DI 2
(Date:12/26/2014)... 26, 2014 The Biofeedback Federation of ... 24-28, 2015 in Rome, Italy and is hosted by ... workshops on a wide variety of topics such ... peak performance training in athletes. The scientific program will ... , Biofeedback monitoring allows clients to see what is ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a ... producing and marketing of a series of induction heating ... new series of induction brazing equipments . , ... induction brazing refers to the joining of two ... heat. The manager says that there are fundamental differences ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... diagnosed incidentally and asymptomatic, 12% to 27 % ... with duodenal diverticula suffer from clinical symptoms. Furthermore, ... various complications such as perforation, hemorrhage, and biliary/pancreatic/gastrointestinal ... the rare complications of diverticulum, based on the ...
... , CHICAGO, Aug. 25 MRSA ... MRSA Day Kick-off event on October 1st in Chicago at Loyola ... the U.S. on October 2nd and throughout the month of October, ... http://www.newscom.com/cgi-bin/prnh/20090825/DC65136LOGO ) , , The historic day ...
... Aug. 25 Zargis Medical Corp., a spin-off from Siemens Corporate Research ... (Nasdaq: SPDE ), today announced that it has begun selling ... MMM ) j u st-released ... previously a n nounced exclusive multi-year global ...
... , AUSTIN, Texas, Aug. 25 Scalpure, LLC ... l oss and proving how effective their ... reporting unprecedented results. Scalpure is available exclusively at http://www.Scalpure.com. ... product that everyone can benefit from. Scalpure creates and maintains ...
... , , , ... NASHVILLE, Tenn., Aug. 25 HealthLeaders-InterStudy, a leading provider of managed care ... consolidated than most large cities, with multiple large physician groups affiliated with ... in the future. According to the recent Chicag o ...
... , , MILWAUKEE, Aug. 25 ... habits, says a national survey by Bradley Corporation, a leading manufacturer ... In Bradley,s first Healthy Hand Washing Survey, 54 percent said ... restrooms since the H1N1 virus emerged. , , ...
Cached Medicine News:Health News:MRSA Survivor to Launch First World MRSA Day 2Health News:Zargis Cardioscan(TM) Unveiled Through Global Marketing and Distribution Alliance With 3M Company 2Health News:Zargis Cardioscan(TM) Unveiled Through Global Marketing and Distribution Alliance With 3M Company 3Health News:Zargis Cardioscan(TM) Unveiled Through Global Marketing and Distribution Alliance With 3M Company 4Health News:Hair Loss Being Conquered 2Health News:Consolidation Among Chicago Physicians Likely to Increase 2Health News:Consolidation Among Chicago Physicians Likely to Increase 3Health News:Despite H1N1 Flu Threat, Most Americans Haven't Increased Hand Washing 2
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
... NEW Research Grade Microscope Camera ... a superior imaging technology that delivers ... accuracy at an affordable price. ... high resolution 3.3 mega-pixel digital microscope ...
The ImagingPlanet 80 mm surgical microscope video adapter: superior optical quality and precise engineering make this 80 mm focal length adapter an excellent decision for use with your Zeiss surgical...
Medicine Products: